Table 3.
Summary of NB studies evaluating MYCN amplification status in peripheral blood using PCR methodology.
| serum/plasma | PCR method | ref. gene | MNA status (−/+) by INSS disease stage |
median blood MYCN ratio by tissue status |
overall sens. (%) | overall spec. (%) | study | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| tissue |
serum/plasma |
||||||||||||||||
| 1 | 2 | 3 | 4 | 4S | 1 | 2 | 3 | 4 | 4S | MNA− | MNA+ | ||||||
| serum | qPCR | RPPH1 | 14/0 | 10/1 | 8/5 | 33/25 | 5/1 | 14/0 | 10/1 | 9/4 | 32/26 | 5/1 | NR | NR | 97 | 99 | [102] |
| serum | qPCR | NAGK | 22/1 | 18/1 | 7/2 | 18/13 | 5/0 | NR | NR | NR | NR | NR | 0.87 | 199.32 | 100 | 100 | [103] |
| serum | qPCR | IL1B | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | 89 | 98 | [104] |
| serum | qPCR | NAGK | 24/10a | 24/10a | 27/16 | 83/41 | 60/6 | 33/1a | 33/1a | 31/12 | 89/35 | 61/5 | NR | NR | 84 | 100 | [105] |
| plasma | qPCR | NAGK | 16/0 | 4/0 | 7/2 | 6/14 | 1/0 | 16/0 | 4/0 | 7/2 | 6/14 | 1/0 | 0.98 | 26.75 | 100 | 100 | [106] |
| serum | qPCR | NAGK | 38/6a | 38/6a | 14/12 | 33/38 | 6/1 | 38/6a | 38/6a | 13/13 | 37/34 | 6/1 | 2.45 | 118.27 | 86 | 95 | [107] |
| serum | qPCR | NAGK | 10/0 | 21/0 | 13/1 | 49/9 | 2/0 | NR | NR | NR | NR | NR | 0.97 | 2.56 | 91 | 98 | [108] |
| plasma | ddPCR | NAGK | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | 2.7 | 49.2 | 100 | 100 | [109] |
aStages 1 and 2 grouped. ddPCR, droplet digital PCR; INSS, International Neuroblastoma Staging System; MNA, MYCN amplification; NR, not reported; qPCR, quantitative real-time PCR; sens., sensitivity; spec., specificity.